Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients

Figure 1

The effect of cytokines on NK cell cytotoxic activity and IFN-γ production. a) In healthy controls (HC) and metastatic melanoma (MM) patients high significant (**p < 0.01, Wilcoxon signed rank test) enhancement of NK cell cytotoxicity is obtained after 18 h in vitro treatment of peripheral blood mononuclear cells (PBMC) with IL-12 alone (10 ng/ml), as well as with IL-12 in combination with IL-18 (100 ng/ml) that gives a significant (*p < 0.05, Wilcoxon signed rank test) increase in HC only; b) In both HC and MM patients IL-12 alone or in combination with IL-18 significantly (*p < 0.05, Wilcoxon signed rank test) or high significantly (**p < 0.01, Wilcoxon signed rank test) increases the percentage and mean fluorescence intensity (MFI) of CD107a degranulation marker on CD3CD56+ NK cells and their CD3CD56dim+ and CD3CD56bright+ subsets, while IL-18 alone significantly (*p < 0.05, Wilcoxon signed rank test) increases the expression of CD107a on NK cells and their subsets only in HC. Results are obtained by Flow cytometry; c) In HC 18 h in vitro treatment of PBMC with combination of IL-12 and IL-18 high significantly (**p < 0.01, Wilcoxon signed rank test) increases the percentage of IFN-γ only in the bright NK cell subset, while this combined cytokine treatment increases the MFI of IFN-γ significantly (*p < 0.05, Wilcoxon signed rank test) in NK cells and their dim subset and high significantly (**p < 0.01, Wilcoxon signed rank test) in the bright NK cell subset. In MM patients the combination of IL-12 and IL-18 significantly (*p < 0.05, Wilcoxon signed rank test) increases only the MFI of IFN-γ in the bright subset. Results are obtained by Flow cytometry. All results are shown as mean ± SE for maximum 26 HC and 36 MM patients.

Back to article page